Document Detail


Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits.
MedLine Citation:
PMID:  11786416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Elevated plasma lipoprotein(a) [Lp(a)] levels constitute an independent risk factor for the development of atherosclerosis. However, the mechanism underlying Lp(a) atherogenicity is unclear. Recently, we demonstrated that Lp(a) may potentially be proatherogenic in transgenic rabbits expressing human apolipoprotein(a) [apo(a)]. In this study, we further investigated atherosclerotic lesions of transgenic rabbits by morphometry and immunohistochemistry. On a cholesterol diet, human apo(a) transgenic rabbits had more extensive atherosclerotic lesions of the aorta, carotid artery, iliac artery, and coronary artery than did nontransgenic littermate rabbits as defined by increased intimal lesion area. Enhanced lesion development in transgenic rabbits was characterized by increased accumulation of smooth muscle cells, that was often associated with the Lp(a) deposition. To explore the possibility that Lp(a) may be involved in the smooth-muscle cell phenotypic modulation, we stained the lesions using a panel of monoclonal antibodies against smooth-muscle myosin heavy-chain isoforms (SM1, SM2, and SMemb) and basic transcriptional element binding protein-2 (BTEB2). We found that a large number of smooth muscle cells located in the apo(a)-containing areas of transgenic rabbits were positive for SMemb and BTEB2, suggesting that these smooth muscle cells were either immature or in the state of activation. In addition, transgenic rabbits showed delayed fibrinolytic activity accompanied by increased plasma plasminogen activator inhibitor-1. We conclude that Lp(a) may enhance the lesion development by mediating smooth muscle cell proliferation and dedifferentiation possibly because of impaired fibrinolytic activity.
Authors:
Tomonaga Ichikawa; Hiroyuki Unoki; Huijun Sun; Hiroaki Shimoyamada; Santica Marcovina; Hisataka Shikama; Teruo Watanabe; Jianglin Fan
Related Documents :
7187826 - Presence of a smooth muscle system in aortic valve leaflets.
11896056 - Molecular and functional characterization of a murine calcium-activated chloride channe...
19621276 - Participation of hsp27 in the antiapoptotic action of 17beta-estradiol in skeletal musc...
18314176 - Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive ...
18245636 - Speed-dependent intrinsic caudal fin muscle recruitment during steady swimming in blueg...
21945656 - Activity of upper limb muscles during human walking.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of pathology     Volume:  160     ISSN:  0002-9440     ISO Abbreviation:  Am. J. Pathol.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-01-11     Completed Date:  2002-07-05     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0370502     Medline TA:  Am J Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  227-36     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Animals, Genetically Modified / genetics
Apolipoproteins A / genetics,  pharmacology,  physiology*
Arteriosclerosis / blood,  pathology*,  physiopathology*
Cell Differentiation / physiology
Cell Division / physiology
Female
Fibrinolysis / drug effects
Humans
Immunohistochemistry / methods
Lipids / blood
Lipoprotein(a) / physiology*
Lipoproteins / blood
Male
Muscle, Smooth, Vascular / pathology*
Plasminogen / metabolism
Plasminogen Activator Inhibitor 1 / blood
Rabbits
Staining and Labeling
Transforming Growth Factor beta / metabolism
Chemical
Reg. No./Substance:
0/Apolipoproteins A; 0/Lipids; 0/Lipoprotein(a); 0/Lipoproteins; 0/Plasminogen Activator Inhibitor 1; 0/Transforming Growth Factor beta; 9001-91-6/Plasminogen
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Androgen receptor expression and cellular proliferation during transition from androgen-dependent to...
Next Document:  Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.